SEMINARS

2013/2014 Program

Implementation mechanisms and impact of the meningitis vaccination in Europe and Africa
 
Organized by A. Opinel (Pharmacoepidemiolgy and Infectious Diseases /UVSQ EA449/INSERM U657) and M. Garenne (Epidemiology of Emerging Diseases), Infection & Epidemiology Department, Institut Pasteur
 
Venue : 1 p.m. Institut Pasteur, 28 rue du Dr Roux 75015 Paris, BIME, 1er étage, salle 28-07-01A and salle Jules Bordet.
http://www.pasteur.fr/ip/easysite/pasteur/fr/institut-pasteur/adresses-et-acces/plan-campus-cote-28
 
These seminars address the issue of meningococcal and pneumococcal meningitis vaccines, and that of the complexity of public health decisions on these new vaccines. The discussion is  organized according to a biogeographical split, since implementation and targets are different whether we consider Africa or Europe. The seminars deal with a variety of technical issues: measure of a vaccine impact, studies of implementation in the field, mathematical model of disease transmission. They also address social, economical and political aspects, especially with respect to disease burden and its politization in the case of control of meningococcal diseases in low income countries.
 
3 octobre 2013
Isabelle Parent du Chatelet (Unité maladies à prévention vaccinale, Département des maladies infectieuses, InVS)
Epidémiologie des infections invasives à  méningocoque en France
 
7 novembre 2013 
Muhamed-Kheir Taha (CNR des méningocoques et infections bactériennes invasives, Institut Pasteur)
Stratégies de  vaccination contre le méningocoque
 
5 décembre 2013
Wiebke Hellenbrand, (Immunization Unit, Department of Infectious Disease Epidemiology Robert Koch Institute, Berlin)
Introduction of meningococcal C vaccination in Germany: Lessons learnt and implications for meningococcal B vaccination
 
9 janvier 2014 
Judith Mueller (EHESP/ Institut Pasteur)
L’impact vaccinal contre les épidémies de méningite dans la Ceinture africaine : méthodes d’évaluation, résultats et défis
 
13 février 2014
Sandra Mounier-Jack (Faculty of Public Health and Policy,  London School of Hygiene and Tropical Medicine)
Men A vaccine in Mali: health systems impact
 
6 mars 2014 
F Marc LaForce, MD, Director, Technical Services, Serum Institute of India, Ltd, Pune, Clinical Professor of Medicine, New York University Langone School of Medicine, New York)
Development, testing, licensure and introduction of a new and affordable Group A meningococcal conjugate vaccine (MenAfriVac) in Africa: challenges and lessons learned
 
3 avril 2014
James Stuart (London School of Hygiene and Tropical Medicine)
Impact of serogroup A vaccine in Chad
 
15 mai 2014
Maurice Cassier (CNRS, Ecole des hautes études en sciences sociales)
Les dispositifs de l’innovation pharmaceutique : le  développement du vaccin MenAfriVac
 
5 juin 2014
Matthieu Domenech de Cellès (University of Michigan) et Marga Pons-Salort (PhEMI, Institut Pasteur)
Exploring mechanisms driving pneumococcal meningitis trends in France, from 2001 to 2009
 
 
Action financée par la Région Ile-de-France




 
Dernière mise à jour : 20 septembre 2013